Sandoz Canada wins Health Canada approval for generic semaglutide, a copy of Ozempic

Sandoz Canada said on September 18, 2026 that Health Canada authorized Sandoz Semaglutide, a generic version of Novo Nordisk's Ozempic, for once-weekly treatment of adults with type 2 diabetes to improve blood sugar control, used alongside lifestyle changes and other diabetes medicines ^[1]. The company called it a lower-cost alternative and said it is preparing for a future launch ^[1].

The Notice of Compliance covers three doses delivered by injection under the skin through two pen presentations: a pen delivering 0.25 mg or 0.5 mg doses, containing 2 mg of semaglutide at 1.34 mg/mL, and a pen delivering 1 mg doses, containing 4 mg of semaglutide at 1.34 mg/mL ^[1]. Sandoz's approved uses mirror Ozempic's diabetes indications, including use with metformin, with metformin plus a sulfonylurea, with an SGLT2 inhibitor, or with basal insulin and metformin when diet and exercise plus those drugs do not control blood sugar ^[1].

A crowded Canadian field

Sandoz is not first. Health Canada assigned drug identification numbers to semaglutide injections made by India-based Dr. Reddy's Laboratories on April 28, 2026, making Canada the first G7 country to approve a generic version of semaglutide ^[2][3]. Novo Nordisk's protection against generics in Canada expired on January 4, 2026 ^[2]. A second generic, from Canadian-based Apotex, was authorized on May 1, 2026, and at that time Health Canada said it was reviewing seven other generic semaglutide submissions and expected more decisions "in the coming weeks and months" ^[3].

Health Canada describes these generics as complex synthetic products that are pharmaceutically equivalent to the brand-name biologic drug, and says its review ensures differences between the products do not affect safety, efficacy or quality ^[1][3]. The agency also noted that in Canada, many generic medications are 45% to 90% cheaper than brand-name versions ^[3].

The brand has already responded on price. Novo Nordisk Canada announced that effective May 29, 2026, eligible Canadians without public or private drug coverage who choose Ozempic would pay less, "aligning their medication costs with generic alternatives" ^[4]. The savings cards can be used at pharmacies across Canada, excluding Quebec ^[4]. Novo said Ozempic was approved in Canada in 2018 and that more than one million Canadians now use semaglutide ^[4]. Sandoz cited IQVIA data indicating close to 12 million semaglutide injection pens are used annually in Canada ^[1].

Why it matters for patients

For people in the United States, the most important detail is a boundary line: a Health Canada authorization allows a product to be marketed in Canada ^[1][3]. None of these approvals give US pharmacies a generic semaglutide to dispense. Whether or when a generic semaglutide will be approved in the United States has not been reported here, and US patent and regulatory timelines are not addressed in these announcements.

The Canadian approvals are also narrower than many people assume. Sandoz Semaglutide was cleared for type 2 diabetes blood sugar control, not for weight loss ^[1]. Ozempic in Canada also carries indications to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or chronic kidney disease, and to reduce the risk of sustained kidney function decline, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease ^[4]. Whether the Sandoz generic carries those same cardiovascular and kidney indications was not stated in its announcement ^[1].

There is a second practical signal for US readers. Novo Nordisk's Canadian move shows that brand pricing can shift quickly once copies arrive ^[4]. That is a Canadian program with Canadian eligibility rules, and it does not extend to US cash-pay or insured patients ^[4].

What happens next

Sandoz said it is taking steps to prepare for commercialization and is developing educational materials for patients and health care professionals ^[1]. A launch date and a Canadian price for Sandoz Semaglutide have not been disclosed ^[1].

More Canadian decisions are likely: Health Canada said in May 2026 that seven additional generic semaglutide submissions from different companies were under review, with rulings expected over following weeks and months ^[3]. The outcome of those reviews has not been reported.